Registration is now open to secure your place at LogiPharma, the world’s leading life sciences supply chain event.
Get 5% off using our exclusive discount code: EVA5LP
This year, accredited members of the media can also sign up to join a virtual press briefing which will cover key agenda topics and highlight the integration of LogiMed into the LogiPharma agenda, creating brand new content specific to the medical device industry.
LogiPharma is a must attend event for journalists covering pharmaceutical and medical device supply chains.
In an increasingly complex world with supply chains integral to the sustainability of international health care systems, representatives from every one of the global top 20 pharmaceutical companies will be speaking or attending the event in Lyon this April.
Global pharmaceutical supply chains have become a leading issue with the increasing pressure on health systems and new treatments requiring more sophisticated logistical solutions.
This year’s agenda includes a keynote case study from Catherine Nihoul, Director Head of Global Covid 19 vaccine logistics at Pfizer on mitigating supply chain issues to drive improvements in global Comirnaty vaccine production and distribution.
With huge steps forward in personalised medicines such as gene therapies, there will also be a discussion from directors in CAR-T therapies at Johnson & Johnson, mRNA and Gene Therapy at Pfizer and other experts on how the industry can mitigate risks and lower costs across the supply chain to ensure these lifesaving treatments reach the end user.
With other keynote addresses including supply chain experts from P&G and Médecins Sans Frontières, LogiPharma and LogiMed provides an unrivalled opportunity to discover the latest developments in the sector and understand from industry leaders the key issues over the next years.
The full agenda is available here.
Centre de Congrès de Lyon, France
25th – 27th April
To secure your place at LogiPharma and LogiMed, please email:
1500hrs CET Monday 24th April
To register to attend the press briefing, please email: